M. H. Moehler Et Al. , "JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).," Gastrointestinal Cancers Symposium , vol.36, San-Francisco, Costa Rica, 2018
Moehler, M. H. Et Al. 2018. JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).. Gastrointestinal Cancers Symposium , (San-Francisco, Costa Rica).
Moehler, M. H., Ryu, M., Lee, K., Coskun, H. S., Wong, R., Ozguroglu, M., ... Chung, H.(2018). JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC). . Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica
Moehler, Markus Et Al. "JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).," Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 2018
Moehler, Markus H. Et Al. "JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).." Gastrointestinal Cancers Symposium , San-Francisco, Costa Rica, 2018
Moehler, M. H. Et Al. (2018) . "JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).." Gastrointestinal Cancers Symposium , San-Francisco, Costa Rica.
@conferencepaper{conferencepaper, author={Markus H. Moehler Et Al. }, title={JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).}, congress name={Gastrointestinal Cancers Symposium}, city={San-Francisco}, country={Costa Rica}, year={2018}}